Clinical trials: Dexamethasone
Multiple Myeloma
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT02548962
- Testing
- Ibrutinib, Pomalidomide, Dexamethasone
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 11 people
- Sponsor
- Pharmacyclics LLC.
Multiple Myeloma
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with…
- Trial name
- EVOLUTION (NCT00507442)
- Testing
- VELCADE (bortezomib), dexamethasone, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Malignant Neoplasm
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid…
- Trial name
- NCT06979596
- Testing
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate
- Where
- 60 sites in United States, Argentina and 11 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Inflammation
Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex
Phase IV, randomized, double-masked, parallel-group clinical trial comparing the ocular tolerability and steroid-induced intraocular pressure (IOP) effects of Zylet wth that of TobraDex in healthy volunteers, when either product…
- Trial name
- NCT00532961
- Testing
- Loteprednol etabonate 0.5% and tobramycin 0.3%, Dexamethasone 0.1% and tobramycin 0.3%
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Multiple Myeloma
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with…
- Trial name
- MajesTEC-3 (NCT05083169)
- Testing
- Daratumumab, Pomalidomide, Dexamethasone
- Where
- 176 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- Janssen Research & Development, LLC
Cancer, Chemotherapy-Induced Nausea and Vomiting
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a phase III study designed to demonstrate the superiority of single-dose 90 mg intravenous (IV) casopitant over placebo, each in combination with ondansetron and dexamethasone, for the prevention of emesis over the first…
- Conditions
- Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
- Trial name
- NCT00891761
- Testing
- Dexamethasone, IV casopitant (active), Ondansetron
- Where
- 3 sites in United States, Canada
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Solid Tumor
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with…
- Trial name
- NCT04300556
- Testing
- Farletuzumab ecteribulin, Prednisone, Prednisolone
- Where
- 58 sites in United States, France and 3 more
- Volunteers
- 182 people
- Sponsor
- Eisai Inc.
Multiple Myeloma
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody…
- Trial name
- DREAMM 5 (NCT04126200)
- Testing
- Belantamab mafodotin, GSK3174998, Feladilimab
- Where
- 38 sites in United States, Brazil and 11 more
- Volunteers
- 208 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma.
- Trial name
- NCT01698801
- Testing
- Lenalidomide, dexamethasone
- Where
- 24 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Celgene
Diabetic Macular Edema
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1…
- Trial name
- NCT03889444
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Allergan
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment.
- Trial name
- NCT07227311
- Testing
- Belantamab mafodotin, Dexamethasone, Pomalidomide
- Where
- 59 sites in United States, France and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy…
- Trial name
- NCT01698281
- Testing
- AEZS-108, SCCC, Dexamethasone
- Where
- 3 sites in United States, Germany
- Volunteers
- 7 people
- Sponsor
- AEterna Zentaris
Prostate Neoplasms
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
The purpose of this study is to provide access to abiraterone acetate for patients who have completed 12 cycles of abiraterone acetate treatment in Clinical Study COU-AA-001 and continue to receive clinical benefit from this…
- Trial name
- NCT01664728
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed/Refractory Multiple Myeloma
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when…
- Trial name
- NCT01794507
- Testing
- ABT-199, bortezomib, dexamethasone
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Leukemia
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia.
- Trial name
- NCT02723994
- Testing
- Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide
- Where
- 111 sites in United States, Canada and 1 more
- Volunteers
- 171 people
- Sponsor
- Incyte Corporation
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi